ARIPIPRAZOLE | N211448 | CMG PHARMACEUTICAL CO LTD
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 3 | Active | Qilu Pharmaceutical Co., Ltd. | 402 | 2025-10-02 → 2026-12 | |
| Phase 2 | Not Yet Recruiting | Washington University School of Medicine | 300 | 2026-10-01 → 2029-09-15 | |
| Phase 2 | Not Yet Recruiting | Christiana Franke | 138 | 2026-10-01 → 2028-12-31 | |
| Phase 2 | Not Yet Recruiting | Vigonvita Life Sciences | 500 | 2026-07-31 → 2027-12-31 | |
| Phase 4 | Recruiting | Northwell Health | 180 | 2024-09-04 → 2030-07-30 | |
| Phase 1 | Recruiting | University of California, San Francisco | 25 | 2025-09-30 → 2027-08-30 | |
| Phase 3 | Recruiting | Minerva Neurosciences | 380 | 2026-04-23 → 2028-12 | |
| Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 1,151 | 2004-09-01 → 2006-12-01 | |
| Phase 4 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 450 | 2005-06-01 → 2007-04-01 | |
| Phase 4 | Completed | Massachusetts General Hospital | 278 | 2017-07-13 → 2022-04-24 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
39 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Aug 4, 2026 | SUPPL -1 | View Letter (PDF) |
| Apr 28, 2025 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|---|---|---|---|---|---|
| 9694008 | Aug 7, 2033 | — | — | Yes | — | — |